Press Release
Waldorf=Astoria Hotel New York City 5:30-7:30 p.m. (ET)
SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it will host an investor reception for institutional investors and analysts at the Waldorf=Astoria Hotel in New York City on Tuesday, September 11, 2007, from 5:30 p.m. to 7:30 p.m. ET.
The reception will be hosted by NuVasive and includes presentations by senior management and top academic and private leading physicians from New York, Washington, DC and Texas. The physicians will participate in an interactive surgeon panel presentation covering key clinical updates, including an update from a surgeon participating in the NeoDisc clinical trial, as well as physician experience with XLIF(R) and new products launched during the first half of 2007 (SpheRx(R) II, XLP(TM) Lateral Plate and Formagraft(R)). Senior management and guest physicians will also participate in a question and answer session.
NuVasive senior management at the reception will include:
* Alex Lukianov, Chairman and Chief Executive Officer
* Keith Valentine, President and Chief Operating Officer
* Kevin O'Boyle, Executive Vice President and Chief Financial Officer
* Pat Miles, Executive Vice President of Marketing and Development
* Jeff Rydin, Senior Vice President, U.S. Sales
* Jason Hannon, Senior Vice President and General Counsel
Participants in the physician panel will include:
* Andrew Cappuccino, MD, Director Buffalo Spine Surgery and Assistant
Clinical Professor at SUNY, Buffalo, NY
* Randall Dryer, MD, Attending Orthopedic Surgeon, Central Texas Spine
Institute, Austin, TX
* Eric Elowitz, MD, Attending Neurosurgeon at St. Luke's-Roosevelt and
Beth Israel Hospitals and Assistant Professor of Neurological Surgery
at Albert Einstein College of Medicine, New York, NY
* Faheem Sandhu, MD, Assistant Professor, Department of Neurosurgery and
Director of Complex and Minimally Invasive Spinal Surgery at Georgetown
University Hospital, Washington, DC.
A live Web cast of the investor reception presentations will be available online from the investor relations page of the Company's corporate Web site at www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, www.nuvasive.com, for 30 days.
About NuVasive
NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $3.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(TM), as well as a growing offering of cervical and motion preservation products.
The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed (particularly with respect to the ongoing clinical trial for NeoDisc(TM)); the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that the Company's financial projections may prove incorrect because of unexpected difficulty in generating sales or achieving anticipated profitability; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made. NuVasive further cautions you that the opinions expressed by the physician- participants in the investor reception are entirely their own, have not been developed or scripted by NuVasive, should not be attributed to NuVasive, and may prove to be inaccurate.
Contact:
Kevin C. O'Boyle
EVP & Chief Financial Officer
NuVasive, Inc.
858-909-1800
investorrelations@nuvasive.com
Investors:
Nick Laudico/Zack Kubow
The Ruth Group
646-536-7030/7020
nlaudico@theruthgroup.com
zkubow@theruthgroup.com
Media:
Jason Rando
The Ruth Group
646-536-7025
jrando@theruthgroup.com
SOURCE NuVasive, Inc.
09/07/2007
CONTACT: Kevin C. O'Boyle, EVP & Chief Financial Officer of NuVasive,
Inc., +1-858-909-1800, investorrelations@nuvasive.com; or Investors, Nick
Laudico, +1-646-536-7030, nlaudico@theruthgroup.com, or Zack Kubow,
+1-646-536-7020, zkubow@theruthgroup.com, or Media, Jason Rando,
+1-646-536-7025, jrando@theruthgroup.com, all of The Ruth Group, for NuVasive,
Inc.
Web site: http://www.nuvasive.com